Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.

bispecific antibodies glofitamab relapsed/refractory diffuse large B-cell lymphoma

Journal

Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268

Informations de publication

Date de publication:
Oct 2023
Historique:
revised: 24 03 2023
received: 25 10 2022
accepted: 02 05 2023
pubmed: 22 5 2023
medline: 22 5 2023
entrez: 22 5 2023
Statut: ppublish

Résumé

Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients with relapsed/refractory (R/R) B-cell lymphoma. However, the real-world data of patients of all ages with no strict selection criteria are still lacking. Herein, this retrospective study aimed to evaluate the outcomes of diffuse large B-cell lymphoma (DLBCL) patients who received glofitamab via compassionate use in Turkey. Forty-three patients from 20 centers who received at least one dose of the treatment were included in this study. The median age was 54 years. The median number of previous therapies was 4, and 23 patients were refractory to first-line treatment. Twenty patients had previously undergone autologous stem cell transplantation. The median follow-up time was 5.7 months. In efficacy-evaluable patients, 21% and 16% of them achieved complete response and partial response, respectively. The median response duration was 6.3 months. The median progression-free survival (PFS) and overall survival (OS) was 3.3 and 8.8 months, respectively. None of the treatment-responsive patients progressed during the study period, and their estimated 1-year PFS and OS rate was 83%. The most frequently reported toxicity was hematological toxicity. Sixteen patients survived, while 27 died at the time of the analysis. The most common cause of death was disease progression. One patient died of cytokine release syndrome during the first cycle after receiving the first dose of glofitamab. Meanwhile, two patients died due to glofitamab-related febrile neutropenia. This is the largest real-world study on the effectiveness and toxicity of glofitamab treatment in R/R DLBCL patients. The median OS of 9 months seems promising in this heavily pretreated group. The toxicity related mortality rates were the primary concerns in this study.

Identifiants

pubmed: 37211991
doi: 10.1002/hon.3174
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

663-673

Informations de copyright

© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.

Références

Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540-1545. https://doi.org/10.1056/nejm199512073332305
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. https://doi.org/10.1182/blood-2017-03-769620
Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155-165. https://doi.org/10.1200/jco.19.00172
Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, singlearm, phase 2 trial. Lancet Oncol. 2021;22(6):790-800. https://doi.org/10.1016/s1470-2045(21)00139-x
Salles G, Duell J, Gonzalez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective,single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-988. https://doi.org/10.1016/s1470-2045(20)30225-4
Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational,multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511-e522. https://doi.org/10.1016/s2352-3026(20)30120-4
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42. https://doi.org/10.1016/s1470-2045(18)30864-7
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56. https://doi.org/10.1056/nejmoa1804980
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852. https://doi.org/10.1016/s0140-6736(20)31366-0
Gonzalez Barca E. Role of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma in the CART era. Front Immunol. 2022;13:909008. https://doi.org/10.3389/fimmu.2022.909008
Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns and opportunities. Blood. 2022;141(5):467-480. blood.2021011994. https://doi.org/10.1182/blood.2021011994
Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959-1970. https://doi.org/10.1200/jco.20.03175
Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2022;22:JCO2201725.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. https://doi.org/10.1200/jco.2013.54.8800
Common Terminology criteria for adverse events (CTCAE) version 4.05. November 27, 2017. Accessed December 31, 2016.
Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231. https://doi.org/10.1056/NEJMoa2206913

Auteurs

Elif Birtas Atesoglu (E)

Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey.

Zafer Gulbas (Z)

Division of Hematology, Anadolu Medical Center, Kocaeli, Turkey.

Ant Uzay (A)

Division of Hematology, Acibadem Atakent Hospital, Istanbul, Turkey.

Muhit Ozcan (M)

Department of Internal Medicine, Division of Hematology, Ankara University Medical Faculty, Ankara, Turkey.

Fahir Ozkalemkas (F)

Department of Internal Medicine, Division of Hematology, Uludag University Medical Faculty, Bursa, Turkey.

Mehmet Sinan Dal (MS)

Division of Hematology, Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara, Turkey.

Hakan Kalyon (H)

Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey.

Olga Meltem Akay (OM)

Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey.

Burak Deveci (B)

Division of Hematology, Medstar Hospital, Antalya, Turkey.

Huseyin Bekoz (H)

Department of Internal Medicine, Division of Hematology, Medipol University Medical Faculty, Istanbul, Turkey.

Omur Gokmen Sevindik (OG)

Department of Internal Medicine, Division of Hematology, Medipol University Medical Faculty, Istanbul, Turkey.

Tayfur Toptas (T)

Department of Internal Medicine, Division of Hematology, Marmara University Medical Faculty, Istanbul, Turkey.

Fergun Yilmaz (F)

Department of Internal Medicine, Division of Hematology, Marmara University Medical Faculty, Istanbul, Turkey.

Derya Koyun (D)

Department of Internal Medicine, Division of Hematology, Ankara University Medical Faculty, Ankara, Turkey.

Nihan Alkis (N)

Division of Hematology, Bursa City Hospital, Bursa, Turkey.

Inci Alacacioglu (I)

Department of Internal Medicine, Division of Hematology, Dokuz Eylul University Medical Faculty, Izmir, Turkey.

Mehmet Sonmez (M)

Department of Internal Medicine, Division of Hematology, Karadeniz Technical University Medical Faculty, Trabzon, Turkey.

Irfan Yavasoglu (I)

Department of Internal Medicine, Division of Hematology, Adnan Menderes University Medical Faculty, Aydin, Turkey.

Anil Tombak (A)

Department of Internal Medicine, Division of Hematology, Mersin University Medical Faculty, Mersin, Turkey.

Ozgur Mehtap (O)

Department of Internal Medicine, Division of Hematology, Kocaeli University Medical Faculty, Kocaeli, Turkey.

Fatih Kurnaz (F)

Division of Hematology, Kocaeli Medicalpark Hospital, Kocaeli, Turkey.

Orhan Kemal Yuce (OK)

Department of Internal Medicine, Division of Hematology, Akdeniz University Medical Faculty, Antalya, Turkey.

Volkan Karakus (V)

Division of Hematology, Antalya Research and Training Hospital, Antalya, Turkey.

Mehmet Turgut (M)

Department of Internal Medicine, Division of Hematology, Ondokuzmayıs University Medical Faculty, Samsun, Turkey.

Derya Deniz Kurekci (DD)

Department of Internal Medicine, Division of Hematology, Ondokuzmayıs University Medical Faculty, Samsun, Turkey.

Mesut Ayer (M)

Division of Hematology, Basaksehir Cam ve Sakura City Hospital, Istanbul, Turkey.

Muzaffer Keklik (M)

Department of Internal Medicine, Division of Hematology, Erciyes University Medical Faculty, Kayseri, Turkey.

Deram Buyuktas (D)

Division of Hematology, V.K.V. American Hospital, Istanbul, Turkey.

Murat Ozbalak (M)

Division of Hematology, Basaksehir Cam ve Sakura City Hospital, Istanbul, Turkey.

Burhan Ferhanoglu (B)

Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey.

Classifications MeSH